Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Sopheon Terug naar discussie overzicht

Sopheon november 2017

35 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. [verwijderd] 14 november 2017 18:11
    gart,ik heb er helemaal geen probleem mee,als er morgen een bod word gedaan op soof, boek dan sluiten van soof, dat heb ik vaker getypt hier.
  2. [verwijderd] 15 november 2017 11:52
    quote:

    Arie de Beuker schreef op 14 november 2017 21:32:

    Waarom wordt er 30 miljoen neergezet en geen 25?

    Gr
    Arie de Beuker

    mogge, dat lezen we wel met de update eind januari.
  3. [verwijderd] 16 november 2017 17:16
    Faster, Better Decision Making for Products, Programs and Enterprise Portfolios in Latest Sopheon Release

    Accolade 11.3 intelligently alerts product leaders on variances from established targets and forecasts to increase transparency and support market success

    Faster, better decision making enabled by Accolade 11.3MINNEAPOLIS—November 16, 2017—Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today released the latest version of its Accolade® Enterprise Innovation Management (EIM) solution.

    It is projected that 75 percent of the S&P 500 will be replaced in the next ten years.1 This eye-opening fact is to some degree a function of the increased rate of change caused by digital disruption. The external market is often moving faster than the companies in the market themselves. This is particularly challenging for product, program and portfolio owners who are challenged to increase their decision making cadence to align with market changes taking place while their products are still in development.

    Accolade 11.3 accelerates strategic investment decision making for products, programs, portfolios and projects by delivering relevant, real-time information and insights to the right people, at the right time – sometimes before they know they need it.

    Daniel Spang, InnoView Manager in the Corporate Innovation department of RENOLIT Group ?said about the latest release:

    “We are excited with the advanced individualization and increased smart capability in Accolade 11.3. These offer increased focus and value to our project and portfolio management processes.”
    Shelly Fetzer, VP of Product at Sopheon, added:

    “With the Accolade 11.3 release we continue to advance the intelligence that Accolade delivers by connecting people to key real-time data within the contexts of corporate strategy and the individual user’s role and responsibilities.”
    Accolade 11.3 Focuses Decisions and Action on Real-Time, Trusted Data

    Product and brand managers gain immediate visibility to out-of-bound conditions, permitting them to act – and react – quickly to achieve critical new product performance commitments such as time to market, revenue, return on investment, and product scope.

    Cross-functional management can now improve the speed and quality of decision making using objective project and product status reporting that is easily standardized and harmonized across portfolios or entire business units.

    Online decision spaces make for more efficient and effective meetings for both decision makers and knowledge workers, with decision-focused information, collaboration and communications.

    Accolade 11.3 is available immediately for upgrade, purchase and implementation. All Sopheon Accolade customers who are current on Maintenance and Support program fees are entitled to receive updates to their currently licensed products for this and future release upgrades. New capabilities in Accolade 11.3 are also available to customers with Accolade Express for PPM deployments. Implementation services may be required.

    1 Richard N. Foster, co-author of Creative Destruction

    About Sopheon
    Sopheon partners with customers to provide complete Enterprise Innovation Management solutions including patented software, expertise, and best practices to achieve exceptional long-term revenue growth and profitability. Sopheon’s Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon’s solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange.
  4. [verwijderd] 17 november 2017 11:07
    mogge, ze geven elke keer die release gratis aan hun klanten, poen moeten ze vragen nikssss gratis, ik zal die mence een keer aan zn flap oren pakken.
  5. [verwijderd] 17 november 2017 12:34
    quote:

    sproetje schreef op 15 november 2017 11:52:

    [...]
    mogge, dat lezen we wel met de update eind januari.
    Juistem.

    Het moge duidelijk zijn dat dergelijke zaken geen typefouten mogen en zullen bevatten!

    Dus we gaan het meemaken.

    Klaas
  6. [verwijderd] 19 november 2017 17:39
    Ze zoeken weer iemand voor redelijk grote bedrijven binnen te halen

    !Sopheon : Sales Executive-Amsterdam
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/17/2017 | 07:06pm CET
    Territory: Companies based in BeNeLux (Netherlands, Belgium and Luxemburg), with a revenue up to 1 billion Euro.

    Responsibilities and Duties The Sopheon team is seeking a 'hunter' sales executive with a proven track record of closing business with new customers in the territory. This role will be largely focused on medium-sized businesses up to 1 billion Euro of revenue. Accolade is very configurable and will be able to cope with a large variety of use cases. Sopheon also has a dedicated approach with embedded best practices called Accolade Express which will be suitable for part of the territory that is (initially) planning to use the best practices embedded in Accolade Express.

    Are you the ideal candidate? Can you demonstrate a track record of the following?

    Business-to-business sales to large complex global firms.
    Expertise in securing access through your own efforts to upper level executives for compelling sales conversations.
    Comfort with C-level relationships in companies up to 1 billion Euro revenue.
    Ability to identify undisclosed customer needs in at least medium sized organizations.
    Team selling and use of all your companies' resources to aid sales process.
    Interpreting public information on a prospect account such as annual reports and stock holder information for account qualification and to identify entry message.
    Understanding strategic selling and the roles of various buying influencers.
    Developing and maintaining a quality pipeline of potential opportunities.
    Driving complex enterprise deals for at least medium sized businesses end to end from personal lead generation and qualification, to solution development and presentation, to contract negotiations, to deal closing and to making sure the deal is property transitioned to support teams. Some coaching and help will be available from the Sopheon Amsterdam team.
    Developing partnerships with relevant players in the Territory, in order to be able to address the local small- and medium-size businesses.
    Awareness and sensibility to local culture as relevant in each individual country in the Territory.
    Building compelling business cases to support proposals and identify return on investment, successfully converting opportunities into license sales and consulting engagements.
    Developing strong relationships with potential clients at SVP, Director and C-levels particularly with prospect R&D, Marketing and Innovation Management functional areas.
    Managing and reporting opportunities pipeline in Salesforce.com.
    Adapting to existing team chemistry and supporting an organization to reach its objectives.
    Experience in selling to vertical markets of consumer packaged goods, industrial manufacturing, chemical, high technology, medical devices, aerospace & defense, automotive.
    Has an existing network of contacts for shortening the sales cycle, particularly within research and development, innovation, marketing and/or general management.
    Skills and Expertise:

    3-5 years' experience in a consultative sales process with complex 'business centric' enterprise deals with at least medium sized firms.
    Experience selling entire innovation management and new product development (NPD) lifecycle solutions.
    Understanding and familiarity of the Stage-Gate product development methodology (preferred).
    Consistently at or averaging above quota €1.5m.
    Ability to develop and maintain executive level relationships.
    Experience selling to the BeNeLux territory with proven track record.
    Preferably experienced in Brand management and other product development related areas.
    Willingness and ability to travel as necessary.
    Native Dutch speaker and Fluent in English. Knowledge of additional languages such as French and/or German are nice to haves.
    Education and Experience:

    Degree in Management, Business, Economics, MBA a plus (or equivalent).
    3-5 years of experience in direct enterprise software field sales.
    Recent evidence of achieving targets of €1.5m plus.
    We seek Sales Leaders with a Passion for:

    Understanding and diagnosing customer business needs and articulating a solution.
    Use of social media to gain contact with appropriate executives.
    Superior communication skills (written, verbal and presentation)
    Ability to utilize PowerPoint or other media to synthesize and present a compelling business case/rationale.
    Exceedingly comfortable with C-level interactions.

    Trinko
  7. OVI 22 november 2017 17:24
    ik heb gisteren nog een klein beetje gekocht, dus er is wel iets van handel.
    gezien de vacatureteksten verwacht ik eind januari toch geode berichten en dito koersen :-)
    gr. OVI
  8. Gartje 22 november 2017 18:29
    Ik kijk altijd op de beurs.nl en daar zag ik al dagen geen beweging, maar zie dat hij vandaag op 3,70 staat.
  9. Gartje 22 november 2017 18:38
    Ik zag het klaas, normaal zie ik de beursbewegingen met volumes op beurs.nl en zo kom ik ook op dit forum, dus er zit weer stijgende lijn in gelukkig.
35 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.285
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.231
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.880
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.155
Aedifica 2 829
Aegon 3.257 320.025
AFC Ajax 537 7.013
Affimed NV 2 5.746
ageas 5.843 109.777
Agfa-Gevaert 13 1.856
Ahold 3.536 73.979
Air France - KLM 1.024 34.305
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.753
Alfen 12 16.143
Allfunds Group 3 1.174
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 326
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.757
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.212
AMG 965 125.617
AMS 3 73
Amsterdam Commodities 303 6.514
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.108
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.588
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.101
Aroundtown SA 1 176
Arrowhead Research 5 9.254
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.628
ASML 1.762 76.750
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 323
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.642
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.660